Last reviewed · How we verify

Tuberculosis Meningitis Treatment Adjunct — Treatment Landscape & Competitive Intelligence

Tuberculosis Meningitis Treatment Adjunct (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tuberculosis Meningitis Treatment Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Merck) · 1 drug in Tuberculosis Meningitis Treatment Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tuberculosis Meningitis Treatment Adjunct:

Cite this brief

Drug Landscape (2026). Tuberculosis Meningitis Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tuberculosis-meningitis-treatment-adjunct. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing